Core Viewpoint - Xuan Zhu Bio-B (02575) has seen a significant stock price increase, rising over 415% from its IPO price of 11.6 HKD to a peak of 59.85 HKD, reflecting strong market interest following the presentation of clinical trial results at the ESMO conference [1] Company Summary - Xuan Zhu Bio-B's stock price reached 59 HKD, with a trading volume of 183 million HKD, marking a 29.67% increase at the time of reporting [1] - The company presented the mid-analysis results of the BRIGHT-3 clinical trial, which evaluates the efficacy and safety of palbociclib combined with letrozole or anastrozole for first-line treatment of HR+/HER2- advanced breast cancer [1] - The BRIGHT-3 study is a randomized, double-blind Phase III clinical trial conducted at 58 centers in China [1] - Based on the mid-study data from BRIGHT-3, the National Medical Products Administration of China accepted the new drug application for palbociclib in combination with aromatase inhibitors for HR+/HER2- advanced breast cancer on May 14 [1]
港股异动 | 轩竹生物-B(02575)涨幅扩大至30% 吡洛西利治疗乳腺癌临床III期研究数据于ESMO公布